



Promoting the Use of Complex Innovative Designs in Clinical Trials

March 20, 2018



WELCOME AND OPENING REMARKS

Aloka Chakravarty, PhD

Acting Director, Office of Biostatistics

Office of Translational Science

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

Today's Meeting Sessions

- **Session I: General Considerations for Complex Adaptive Clinical Trial Designs to Support the Effectiveness and Safety of Drugs or Biologics**
- **Session II: General Considerations for Other Innovative Designs Including External/Historical Control Subjects, Bayesian Designs, and Master Protocols**
- **Session III: Clinical Trial Simulations for Confirmatory Trial Design and Planning**
- **Session IV: Complex Innovative Design Pilot Program**
- **Closing Remarks**